Chugai Pharmaceutical Co., Ltd. · TSE:4519

Chugai Pharmaceutical — Q3 2011 Earnings Presentation

17 slides from Chugai Pharmaceutical's earnings presentation, Oct 21, 2011

  1. Slide 1: FY2011 3Q Consolidated Financial Overview

    FY2011 3Q Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., CO LTD LTD. Senior Vice President and CFO Yoshio Itaya October 21, 2011

  2. Slide 2: Forward Looking Statements

    FY2011 3Q Consolidated Financial Overview Forward Looking Statements Forward-Looking This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect fl t the th Company’s C ’ currentt analy

  3. Slide 3: Summary

    FY2011 3Q Consolidated Financial Overview Summary  Revenues R 276 276.0 0 billion billi JPY ((-0.1 0 1 billi billion JPY) JPY): flat growth due to reduced Tamiflu sales • Tamiflu: stockpiling p g sales closing g out • Sales excl. Tamiflu: Overseas sales: 28% growth led by strong Actemra export Dome

  4. Slide 4: Financial Overview Jan - Sep

    Year on Year FY2011 3Q Consolidated Financial Overview Financial Overview Jan - Sep (Billion JPY) 2010 2011 (Billi JPY) (Billion As % of As % of G Growth th  Sales excl. Tamiflu Jan-Sep Revenues Jan-Sep Revenues % Domestic -3.5 Revenues 276.1 276.0 -0.1 -0.0 Overseas +7.3 Sales 273.3 267.5 -5.8 -2.

  5. Slide 5: Sales (excl. Tamiflu) Jan - Sep

    Year on Year FY2011 3Q Consolidated Financial Overview Sales (excl (excl. Tamiflu) Jan - Sep (Billion JPY) Sales (excl. Tamiflu) 261.2 (+3.8, +1.5%) 257.4 Actemra A t Epogin E i Overseas (overseas) -6.7 (22.5) +8.3 +7.3, +28.0% (18.8) 26.1 33.4 Others Kytril 27.1 -1.9, -7.0% 25.2 -1.8 ((2.5)) Avasti

  6. Slide 6: Tamiflu Sales Performance

    FY2011 3Q Consolidated Financial Overview Tamiflu Sales Performance Fiscal Term Sales (Billion JPY) FY2005.12 FY2006.12 FY2007.12 FY2008.12 FY2009.12 FY2010.12 FY2011.12 C a se s p e r Seasonal se n ti n e l * Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Ju

  7. Slide 7: Operating Income Jan - Sep

    Year on Year FY2011 3Q Consolidated Financial Overview Operating Income Jan - Sep (Billion JPY) (Billi (Billion JPY) 2010 2011 V i Variance Jan-Sep Jan-Sep (%) Revenues 276.1 276.0 -0.1 -0.0 Cost of Sales 119.6 115.4 -4.2 -3.5 IIncrease in i Decrease in SG&A R&D exp. Gross Profit 156.5 160.7 +4.2 +2

  8. Slide 8: Impact of the Great East Japan Earthquake

    FY2011 3Q Consolidated Financial Overview Impact of the Great East Japan Earthquake  Loss on disaster: 7.4 7 4 billion JPY (Jan – Sep) Fixed costs during shut down increased (Jan-Jun: 6.5 billion JPY) • Buildings and equipment (costs of retirement, demolition and restoration): 4.2 billion JPY • Los

  9. Slide 9: Financial Overview Jul - Sep

    Year on Year FY2011 3Q Consolidated Financial Overview Financial Overview Jul - Sep (Billion JPY) 2010 2011 (Billion JPY) Growth  Sales excl. Tamiflu +2.2 As % of As % of Jul-Sep Revenues Jul-Sep Revenues % Revenues 93.7 94.1 +0.4 +0.4 Mircera +2.8 Sales 92.6 92.7 +0.1 +0.1 Actemra (domestic) +0.9

  10. Slide 10: Financial Overview Jan - Sep vs. Forecast

    vs. Forecast FY2011 3Q Consolidated Financial Overview Financial Overview Jan - Sep Sales Progress Actual Forecast on Jul. 21 Sales excl. Tamiflu 69.8% (Billion JPY) 2011 2011 Domestic 67.6% Progress Jan-Sep Jan-Dec (%) Oncology 67.4% R Revenues 276 0 276.0 395 2 395.2 69 8 69.8 Herceptin 76.0% Sale

  11. Slide 11: Impact from Foreign Exchange

    vs. Forecast FY2011 3Q Consolidated Financial Overview Impact from Foreign Exchange FX impacts Jan Jan-Jun Jun FX impacts Jul Jul-Sep Sep FX rate t to t the th JPY 1CHF 1EUR (Billion JPY) (vs. forecast on Apr 21) (vs. forecast on Jul 21) Assumption Jan – Dec 85.00 110.00 as of Apr 21* +1.0 +0.1 Actu

  12. Slide 12: Overview of Development Pipeline

    Overview of Development Pipeline CHUGAI PHARMACEUTICAL CO., LTD. LTD Department Manager R&D Portfolio Management Dept. Hisanori Takanashi October 21, 2011

  13. Slide 13: Development Status - Oncology (1)

    Overview of Development Pipeline Development Status - Oncology (1) In- licensed Avastin : Breast cancer Approved in Sep. 2011 In- licensed GA101(RG7159) : Indolent NHL, Aggressive NHL Decided to p participate p in P3 multinational study y 13

  14. Slide 14: Development Status - Oncology (2)

    Overview of Development Pipeline Development Status - Oncology (2) In- house WT4869 (WT1 peptide cancer vaccine): Solid tumors Started P1 in Sep. 2011 In- licensed RG3638 (MetMAb) : Non-small Non small cell cancer Started P1 in Aug. 2011 In-hous e Epogin : Chemotherapy-induced anemia Received unappr

  15. Slide 15: Development Status - Bone & Joint, Transplant, Immunology, Infectious diseases and others

    Overview of Development Pipeline Development p Status－ Bone & Joint, Transplant, Immunology, Infectious diseases and others In-hous In hous e Actemra (EU): sJIA Approved in Aug. 2011 In- licensed Pegasys: HBV Approved in Sep Sep. 2011 In- licensed RG3637 (lebrikizumab) : Asthma Started P1 in Aug. 20

  16. Slide 16: New Projects Focused on PHC

    Overview of Development Pipeline New Projects Focused on PHC  MetMAb: Non-small cell lung g cancer  Patient population: 60,000 (Advanced/Recurrent)  Companion diagnostics: Met diagnostic-positive (>50%)  vemurafenib: Melanoma  Plan to start Japanese P1 study in 2012  Patient population: newly

  17. Slide 17: Contacts: Corporate Communications Dept.

    Contacts: Corporate Communications Dept. Corporate Communications Group Tel: +81 (0)3-3273-0881 (0)3 3273 0881 Fax: +81 (0)3 (0)3-3281-6607 3281 6607 e-mail: [email protected] Hitoshi Aikawa, Koichi Kawahara, Kae Miyata, Hiroshi Araki Investor Relations Group Tel: T l +81 (0)3 (0)3-3273-0554 327

Chugai Pharmaceutical — Q3 2011 Earnings Presentation on 6ix